Literature DB >> 7783912

Experimental autoimmune encephalomyelitis: immunotherapy with anti-tumor necrosis factor antibodies and soluble tumor necrosis factor receptors.

K W Selmaj1, C S Raine.   

Abstract

Multiple sclerosis (MS) is a demyelinating disease in which an inflammatory cell infiltrate represents a characteristic pathologic feature of active lesions within the CNS. The possibility has been raised that cell-mediated immune mechanisms orchestrate the pathogenesis of MS. Cytokines play a particularly important role in cellular immune mechanisms. These soluble glycoproteins, nonimmunoglobulin in nature, act nonenzymatically to regulate immune cell function. A unique family of cytokines, the tumor necrosis factors (TNFs), demonstrate immunoregulatory activity but are also involved in the effector arm of cellular immune responses. Recently, studies both in vitro and in vivo have suggested a role for TNFs in the pathology of MS. This report summarizes data implicating TNFs in the mechanisms of MS and attempts to apply the anti-TNF approach in the future therapeutic strategy for this disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7783912     DOI: 10.1212/wnl.45.6_suppl_6.s44

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  24 in total

1.  Age dependence of clinical and pathological manifestations of autoimmune demyelination. Implications for multiple sclerosis.

Authors:  M E Smith; N L Eller; H F McFarland; M K Racke; C S Raine
Journal:  Am J Pathol       Date:  1999-10       Impact factor: 4.307

Review 2.  Human polyomavirus JC reactivation and pathogenetic mechanisms of progressive multifocal leukoencephalopathy and cancer in the era of monoclonal antibody therapies.

Authors:  A Bellizzi; C Nardis; E Anzivino; D M Rodìo; D Fioriti; M Mischitelli; F Chiarini; V Pietropaolo
Journal:  J Neurovirol       Date:  2012-02       Impact factor: 2.643

3.  CNS demyelination during anti-tumor necrosis factor alpha therapy.

Authors:  Michele Bellesi; Francesco Logullo; Paolo Di Bella; Leandro Provinciali
Journal:  J Neurol       Date:  2005-11-29       Impact factor: 4.849

4.  New-onset demyelination induced by infliximab therapy in two rheumatoid arthritis patients.

Authors:  Makoto Tanno; Ichiro Nakamura; Shunsuke Kobayashi; Kumiko Kurihara; Katsumi Ito
Journal:  Clin Rheumatol       Date:  2006-11       Impact factor: 2.980

5.  alpha-MSH modulates local and circulating tumor necrosis factor-alpha in experimental brain inflammation.

Authors:  N Rajora; G Boccoli; D Burns; S Sharma; A P Catania; J M Lipton
Journal:  J Neurosci       Date:  1997-03-15       Impact factor: 6.167

Review 6.  The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games.

Authors:  Thomas Hehlgans; Klaus Pfeffer
Journal:  Immunology       Date:  2005-05       Impact factor: 7.397

Review 7.  Cytokine-induced inflammation in the central nervous system revisited.

Authors:  J A Martiney; C Cuff; M Litwak; J Berman; C F Brosnan
Journal:  Neurochem Res       Date:  1998-03       Impact factor: 3.996

8.  Microglial production of TNF-alpha is induced by activated T lymphocytes. Involvement of VLA-4 and inhibition by interferonbeta-1b.

Authors:  S Chabot; G Williams; V W Yong
Journal:  J Clin Invest       Date:  1997-08-01       Impact factor: 14.808

Review 9.  New-onset multiple sclerosis associated with adalimumab treatment in rheumatoid arthritis: a case report and literature review.

Authors:  Takumi Matsumoto; Ichiro Nakamura; Ayumi Miura; Gen Momoyama; Katsumi Ito
Journal:  Clin Rheumatol       Date:  2012-11-14       Impact factor: 2.980

10.  Pro-inflammatory cytokines derived from West Nile virus (WNV)-infected SK-N-SH cells mediate neuroinflammatory markers and neuronal death.

Authors:  Mukesh Kumar; Saguna Verma; Vivek R Nerurkar
Journal:  J Neuroinflammation       Date:  2010-10-31       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.